Eisai Co. Ltd.

In News

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan - Eisai

Eisai - Jun 02, 2025

Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) - ACN Newswire

ACN Newswire - Apr 21, 2026

Jefferies Maintains EISAI CO LTD(ESALF.US) With Hold Rating, Raises Target Price to $31.49 - 富途牛牛

富途牛牛 - Apr 14, 2026

Jefferies Maintains EISAI CO LTD(ESALF.US) With Hold Rating, Raises Target Price to $31.49 - Moomoo

Moomoo - Apr 14, 2026

Eisai strikes Japan licensing deal with Shanghai Henlius Biotech - Reuters

Reuters - Feb 05, 2026

Eisai Co. Ltd. (4523.T) Stock Price, News & Analyst Forecast - eToro

eToro - Apr 15, 2026

Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting - BioSpace

BioSpace - Apr 10, 2026

EISAI TO BEGIN ENROLLING PHASE 2 STUDY IN PATIENTS WITH NARCOLEPSY - PR Newswire

PR Newswire - Mar 26, 2026

Eisai Co., Ltd. 2026 Q3 - Results - Earnings Call Presentation (OTCMKTS:ESAIY) 2026-02-09 - Seeking Alpha

Seeking Alpha - Feb 09, 2026

Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi - Bolsamania

Bolsamania - Apr 22, 2026

Eisai Co., Ltd. (TSE:4523) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - simplywall.st

simplywall.st - Feb 11, 2026

Eisai Co Ltd Receives Orphan Drug Designation In Japan For Novel Orexin 2 Receptor Agonist E2086 - BioPharma APAC

BioPharma APAC - Feb 17, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment